PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders platelet aggregation coronary artery disease myocardial infarction transient ischemic attack angina stroke ischemia-reperfusion injury restenosis atrial fibrillation blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation atherosclerosis atherothrombosis asthma or a symptom thereof a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy glaucoma or other disease of the eye with abnormal intraocular pressure hypertension inflammation psoriasis psoriatic arthritis rheumatoid arthritis Crohns disease transplant rejection multiple sclerosis systemic lupus erythematosus (SLE) ulcerative colitis ischemia-reperfusion injury restenosis atherosclerosis acne type 1 diabetes type 2 diabetes sepsis and chronic obstructive pulmonary disorder (COPD).Dérivés de pyrazole de Formule Ia et compositions pharmaceutiques les incluant qui modulent lactivité du récepteur PGI2. Les composés selon la présente invention et les compositions pharmaceutiques les incluant sont destinés à des méthodes pouvant être employées dans le traitement des pathologies suivantes : hypertension artérielle pulmonaire (HTAP) et troubles apparentés agrégation plaquettaire coronaropathie infarctus du myocarde accident ischémique transitoire angine de poitrine accident vasculaire cérébral lésions dischémie-reperfusion resténose fibrillation auriculaire formation dun caillot sanguin au cours dune chirurgie dangioplastie ou de pontage coronarien chez un individu le nécessitant ou chez un individu souffrant de fibrillation auriculaire athérosclérose athérothrombose asthme ou lun d
